PROCEPT BioRobotics (PRCT) experienced a sharp decline of 7.43% during intraday trading on Wednesday, as the market digested the company's latest financial updates.
The movement coincided with the release of PROCEPT BioRobotics' first-quarter 2026 financial results, which included an adjusted EBITDA of USD -18.122 million, compared to the IBES estimate of USD -18.7 million. Additionally, the company provided its full-year revenue growth outlook of 27-33%.
While the EBITDA figure surpassed expectations, the overall earnings report and forward guidance appear to have fallen short of investor hopes, triggering the significant sell-off in the session.
Comments